Skip to content

Trinity Biotech Premier Hb9210 HbA1c Analyzer - 1 eachRecalls & reported problems

Primus Corporation · Hemoglobin A1c assay, Premier Hb9210 HbA1c Analyzer · Class 2

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 05391516744751), received between May 1, 2025 and May 1, 2025 — classified as 1 malfunction.

The most frequently reported specific device problem is “Unexpected Therapeutic Results” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 1 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Unexpected Therapeutic Results1

Patient problems

  • Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • MalfunctionMay 1, 2025Unexpected Therapeutic Results; Unexpected Therapeutic Results

    ON (B)(6) 2025, THE CUSTOMER STATED THAT THEY OBSERVED ERROR CODES DURING ONE SHIFT WHILE OPERATING THE PREMIER HB9210 HBA1C SYSTEM, AND THE SAMPLES WERE LEFT FOR THE NEXT SHIFT TO RUN. THE NEXT SHIFT RAN THE QC, WHICH FAILED. THEY THEN PROCEED TO REPLACE THE COLUMNS ON TO THE SYSTEM, RECALIBRATED, AND THEN RAN QC. WITH PASSING QC, PATIENT SAMPLES WERE RAN AND IT WAS OBSERVED THAT 70% OF THE SAMPLES DID NOT MEET "MATCHING" CRITERIA BETWEEN PREMIER HB9210 ANALYZERS. THE CUSTOMER STATES THAT THEIR CRITERIA IS THE SAMPLES MUST MATCH WITHIN 8%, BUT THEY SAID THEY OBSERVED 15-30% VARIATION BETWEEN THE SAMPLES RAN ON THE DIFFERENT ANALYZERS. THE CUSTOMER STATES THAT THEY PERFORMED A LOOK BACK ON PREVIOUSLY RAN PATIENT RESULTS AND OBSERVED 800 SAMPLES THAT DID NOT MEET THEIR "MATCHING" CRITERIA AND THE TESTS WERE REPEATED. TRINITY BIOTECH ARE NOT ABLE TO CONFIRM IF THE PATIENT DATA WAS AUTOMATICALLY RELEASED FROM THEIR LABORATORY INFORMATION SYSTEM (LIS). THE CUSTOMER STATED THAT A NOTIFICATION WAS SENT FOR THE 800 POTENTIALLY DISCREPANT RESULTS. BASED ON THESE NOTIFICATIONS, THE CUSTOMER CLAIMS THAT THEY HAVE BEEN ADVISED THAT SOME PATIENTS HAD BEEN INCORRECTLY PRESCRIBED MEDICATION. CUR

    Patient problems: Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available

    MAUDE report 21945095 ↗

Other Assay, Glycosylated Hemoglobin devices

All Assay, Glycosylated Hemoglobin devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page